NCT06467773 TSPO-PET/MRI in Surveillance of Neuroinflammation in the Central Nervous System
| NCT ID | NCT06467773 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tongji Hospital |
| Condition | Central Nervous System Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-07-01 |
| Primary Completion | 2029-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-07-01 with a primary completion date of 2029-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Central Nervous System (CNS) inflammation is an immune response activated in the brain and spinal cord by microglial cells and astrocytes, commonly occurring under conditions such as central nervous system ischemia, autoimmunity, infection, toxins, and trauma. Microglial cells, as the innate immune cells of the central nervous system, are responsible for driving the inflammatory response and play a crucial role in sensing environmental changes, responding to harmful stimuli, and engulfing dead neurons. They also present antigens to T lymphocytes, mediating interactions between the peripheral immune system and the central nervous system. Factors released by neuronal cells can either promote or inhibit inflammation, and monitoring the level of inflammation driven by microglial cells is essential for the diagnosis and treatment of central nervous system diseases. MRI is the primary imaging method for central nervous system inflammation, but it can be challenging to diagnose. PET/MR, a technology that integrates PET and MR imaging, provides high-quality diagnostic images and is valuable for the early detection, diagnosis, and assessment of central nervous system diseases. The radioactive ligand 18F-DPA-714 PET, targeting the translocation protein (TSPO), can visualize activated microglial cells, which may have a gain effect in detecting active central nervous system inflammation. This study aims to explore the application of 18F-DPA-714 PET/MR in the early diagnosis, treatment evaluation, and prognosis of central nervous system inflammation.
Eligibility Criteria
Inclusion Criteria: -Clinical diagnosis of ischemic stroke, autoimmune ecephalitis, Neuromyelitis optica spectrum disorders, or multiple sclerosis, etc.al Exclusion Criteria: * Claustrophobia * Metal Implants * Pregancy * Breast-feeding * Renal insufficiency (GFR \< 60 mL/min/1.73m2) * Allergy or other contraindication to gadolinium-based MR contrast agent
Contact & Investigator
Wei Wang, MD
PRINCIPAL INVESTIGATOR
Tongji Hospital
Frequently Asked Questions
Who can join the NCT06467773 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Central Nervous System Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06467773 currently recruiting?
Yes, NCT06467773 is actively recruiting participants. Contact the research team at zhouluoqi@tjh.tjmu.edu.cn for enrollment information.
Where is the NCT06467773 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT06467773 clinical trial?
NCT06467773 is sponsored by Tongji Hospital. The principal investigator is Wei Wang, MD at Tongji Hospital. The trial plans to enroll 100 participants.